You are here

  • Home
  • Archive
  • Volume 94, Issue 6
  • Dolutegravir use in combination with rifampicin-based tuberculosis therapy: 3 years of real-world experience in a large UK teaching hospital

Article Text

Article menu
Download PDFPDF
Letter
Dolutegravir use in combination with rifampicin-based tuberculosis therapy: 3 years of real-world experience in a large UK teaching hospital
  1. Muge Cevik1,2,
  2. Hugh McGann3
  1. 1 Specialist Virology Centre, Royal Infirmary of Edinburgh, Edinburgh, UK
  2. 2 Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, UK
  3. 3 Department of Infection and Travel Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  1. Correspondence to Dr Muge Cevik, Specialist Virology Centre, Royal Infirmary of Edinburgh, Little France, Edinburgh EH16 4SA, UK; muge.cevik{at}nhs.net

https://doi.org/10.1136/sextrans-2018-053698

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Dolutegravir is a substrate of UGT1A1 and CYP3A4, both of which are induced by rifampicin.1 Coadministration with rifampicin results in decreases in dolutegravir plasma exposure, requiring doubling of the daily dose of dolutegravir.1 Preliminary results of a phase III study (INSPIRING) evaluating the safety of dolutegravir use (50 mg twice daily) in combination with rifampicin were recently presented at the Conference on Retroviruses and Opportunistic Infections.2 At 24 weeks, 81% (56/69) of HIV/TB …

    View Full Text

    Footnotes

    • Contributors MC and HM have planned the audit. MC generated and analysed the data, and drafted the first manuscript. Both authors contributed to the final manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.